Vaccines: past, present and future

被引：350

作者：

Plotkin, SA ^{[1
]}

机构：

[1] Univ Penn, Doylestown, PA 18901 USA

来源：

NATURE MEDICINE | 2005年 / 11卷 / 04期

关键词：

D O I：

10.1038/nm1209

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The vaccines developed over the first two hundred years since Jenner's lifetime have accomplished striking reductions of infection and disease wherever applied. Pasteur's early approaches to vaccine development, attenuation and inactivation, are even now the two poles of vaccine technology. Today, purification of microbial elements, genetic engineering and improved knowledge of immune protection allow direct creation of attenuated mutants, expression of vaccine proteins in live vectors, purification and even synthesis of microbial antigens, and induction of a variety of immune responses through manipulation of DNA, RNA, proteins and polysaccharides. Both noninfectious and infectious diseases are now within the realm of vaccinology. The profusion of new vaccines enables new populations to be targeted for vaccination, and requires the development of routes of administration additional to injection. With all this come new problems in the production, regulation and distribution of vaccines.

引用

页码：S5 / S11

页数：7

共 87 条

[1] Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine [J].

Amara, RR ;

Villinger, F ;

Altman, JD ;

Lydy, SL ;

O'Neil, SP ;

Staprans, SI ;

Montefiori, DC ;

Xu, Y ;

Herndon, JG ;

Wyatt, LS ;

Candido, MA ;

Kozyr, NL ;

Earl, PL ;

Smith, JM ;

Ma, HL ;

Grimm, BD ;

Hulsey, ML ;

McClure, HM ;

McNicholl, JM ;

Moss, B ;

Robinson, HL .

VACCINE, 2002, 20 (15) :1949-1955

[2]

[Anonymous], J COMMUNITY HLTH

[3] Vaccine development to prevent cytomegalovirus disease: Report from the National Vaccine Advisory Committee [J].

Arvin, AM ;

Fast, P ;

Myers, M ;

Plotkin, S ;

Rabinovich, R .

CLINICAL INFECTIOUS DISEASES, 2004, 39 (02) :233-239

[4]

ASSAAD F, 1982, B WORLD HEALTH ORGAN, V60, P231

[5]

AUTRAN B, 2002, PRACTICAL GUIDELINES, P65

[6] Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines [J].

Baker, CJ ;

Paoletti, LC ;

Rench, MA ;

Guttormsen, HK ;

Edwards, MS ;

Kasper, DL .

JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (06) :1103-1112

[7] Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine [J].

Belshe, RB ;

Gruber, WC ;

Mendelman, PM ;

Cho, I ;

Reisinger, K ;

Block, SL ;

Wittes, J ;

Iacuzio, D ;

Piedra, P ;

Treanor, J ;

King, J ;

Kotloff, K ;

Bernstein, DI ;

Hayden, FG ;

Zangwill, K ;

Yan, LH ;

Wolff, M .

JOURNAL OF PEDIATRICS, 2000, 136 (02) :168-175

[8] Lipopeptide vaccines - yesterday, today, and tomorrow [J].

BenMohamed, L ;

Wechsler, SL ;

Nesburn, AB .

LANCET INFECTIOUS DISEASES, 2002, 2 (07) :425-431

[9] Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12 [J].

Bernstein, DI ;

Smith, VE ;

Sherwood, JR ;

Schiff, GM ;

Sander, DS ;

DeFeudis, D ;

Spriggs, DR ;

Ward, RL .

VACCINE, 1998, 16 (04) :381-387

[10] Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV [J].

Buckner, C ;

Gines, LG ;

Saunders, CJ ;

Vojtech, L ;

Srivastava, I ;

Gettie, A ;

Bohm, R ;

Blanchard, J ;

Barnett, SW ;

Safrit, JT ;

Stamatatos, L .

VIROLOGY, 2004, 320 (01) :167-180

← 1 2 3 4 5 6 7 8 9 →